Cross-Sector entity
Jan van de Winkel is most often covered alongside Genmab A/S, which appears in 2 of these 2 stories. Coverage clusters in earnings, which accounts for 1 of those 2, with the remainder spread across 1 other category. We currently track 2 Cross-Sector stories that mention Jan van de Winkel, all published on February 19, 2026.
2 verified stories tracked
Last mentioned: Feb 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Jan van de Winkel is most often covered alongside Genmab A/S, which appears in 2 of these 2 stories. Coverage clusters in earnings, which accounts for 1 of those 2, with the remainder spread across 1 other category. We currently track 2 Cross-Sector stories that mention Jan van de Winkel, all published on February 19, 2026. Each carries 2 original sources on average.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Jan van de Winkel. Shared-story counts are live from our verified record — not editorial picks.
Genmab A/S reported full-year 2025 revenue of $3.72 billion, missing analyst estimates despite strong growth in its core oncology portfolio. The company is prioritizing long-term growth through its $1.8 billion ProfoundBio acquisition and the global rollout of Epkinly, leading to a temporary contraction in net profit margins.
Genmab reported full-year 2025 revenue of $3.72B, missing analyst estimates by $50M, while initiating a robust 2026 outlook focused on proprietary oncology assets. Despite a dip in full-year profit, the company is accelerating its transition from a royalty-dependent model to a self-sustaining commercial powerhouse.
Source: insidermonkey.com · seekingalpha.com
